Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 337

1.

Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies.

Darvishian M, Wong S, Binka M, Yu A, Ramji A, Yoshida EM, Wong J, Rossi C, Butt ZA, Bartlett S, Pearce ME, Samji H, Cook D, Alvarez M, Chong M, Tyndall M, Krajden M, Janjua NZ.

J Viral Hepat. 2019 Oct 30. doi: 10.1111/jvh.13228. [Epub ahead of print]

PMID:
31664755
2.

Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis.

Bai Z, Bernardi M, Yoshida EM, Li H, Guo X, Méndez-Sánchez N, Li Y, Wang R, Deng J, Qi X.

Aging (Albany NY). 2019 Oct 8;11(19):8502-8525. doi: 10.18632/aging.102335. Epub 2019 Oct 8.

3.

"Another thing to live for": Supporting HCV treatment and cure among Indigenous people impacted by substance use in Canadian cities.

Pearce ME, Jongbloed K, Demerais L, MacDonald H, Christian WM, Sharma R, Pick N, Yoshida EM, Spittal PM, Klein MB.

Int J Drug Policy. 2019 Dec;74:52-61. doi: 10.1016/j.drugpo.2019.08.003. Epub 2019 Sep 13.

4.

Application of Risk Scores in the Daily Management of Primary Biliary Cholangitis: Response to Corpechot and Chazouillères.

Efe C, Taşçilar K, Montano-Loza AJ, Yoshida EM, Wahlin S.

Am J Gastroenterol. 2019 Oct;114(10):1692. doi: 10.14309/ajg.0000000000000391. No abstract available.

PMID:
31503018
5.

Patients' Perspectives on Early Liver Transplantation in Alcohol-Related Liver Disease.

Wong E, Mullins PD, Wallach JP, Yoshida EM, Erb SR, Ford JA, Scudamore CH, Marquez V.

Hepatol Commun. 2019 Jun 17;3(8):1022-1031. doi: 10.1002/hep4.1390. eCollection 2019 Aug.

6.

Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.

Efe C, Taşçilar K, Henriksson I, Lytvyak E, Alalkim F, Trivedi H, Eren F, Eliasson J, Beretta-Piccoli BT, Fischer J, Calişkan AR, Chayanupatkul M, Coppo C, Ytting H, Purnak T, Muratori L, Werner M, Muratori P, Rorsman F, Önnerhag K, Günşar F, Nilsson E, Heurgué-Berlot A, Güzelbulut F, Demir N, Gönen C, Semela D, Aladağ M, Kiyici M, Schiano TD, Montano-Loza AJ, Berg T, Ozaslan E, Yoshida EM, Bonder A, Marschall HU, Wahlin S.

Am J Gastroenterol. 2019 Jul;114(7):1101-1108. doi: 10.14309/ajg.0000000000000290.

PMID:
31241547
7.

Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.

Borgia SM, Dearden J, Yoshida EM, Shafran SD, Brown A, Ben-Ari Z, Cramp ME, Cooper C, Foxton M, Rodriguez CF, Esteban R, Hyland R, Lu S, Kirby BJ, Meng A, Markova S, Dvory-Sobol H, Osinusi AO, Bruck R, Ampuero J, Ryder SD, Agarwal K, Fox R, Shaw D, Haider S, Willems B, Lurie Y, Calleja JL, Gane EJ.

J Hepatol. 2019 Oct;71(4):660-665. doi: 10.1016/j.jhep.2019.05.028. Epub 2019 Jun 11.

8.

Choosing Wisely Canada-Top Five List in Hepatology: Official Position Statement of the Canadian Association for the Study of the Liver (CASL) and Choosing Wisely Canada (CWC).

Brahmania M, Renner EL, Coffin CS, Yoshida EM, Wong P, Zeman M, Shah H.

Ann Hepatol. 2019 Jan - Feb;18(1):165-171. doi: 10.5604/01.3001.0012.7908.

9.

Occult central pontine myelinolysis post liver transplant: A consequence of pre-transplant hyponatremia.

Zhu J, Al-Alkim F, Hussaini T, Vertinsky A, Byrne D, Erb SR, Stoessl AJ, Yoshida EM.

Ann Hepatol. 2019 Jul - Aug;18(4):651-654. doi: 10.1016/j.aohep.2019.01.004. Epub 2019 Apr 24.

10.

Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy.

Janjua NZ, Darvishian M, Wong S, Yu A, Rossi C, Ramji A, Yoshida EM, Butt ZA, Samji H, Chong M, Chapinal N, Cook D, Alvarez M, Tyndall M, Krajden M; British Columbia Hepatitis Testers Cohort Team.

Hepatol Commun. 2019 Jan 10;3(4):478-492. doi: 10.1002/hep4.1307. eCollection 2019 Apr.

11.

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.

Boni C, Janssen HLA, Rossi M, Yoon SK, Vecchi A, Barili V, Yoshida EM, Trinh H, Rodell TC, Laccabue D, Alfieri A, Brillo F, Fisicaro P, Acerbi G, Pedrazzi G, Andreone P, Cursaro C, Margotti M, Santoro R, Piazzolla V, Brunetto MR, Coco B, Cavallone D, Zhao Y, Joshi A, Woo J, Lau AH, Gaggar A, Subramanian GM, Massetto B, Fung S, Ahn SH, Ma X, Mangia A, Ferrari C.

Gastroenterology. 2019 Jul;157(1):227-241.e7. doi: 10.1053/j.gastro.2019.03.044. Epub 2019 Mar 28.

PMID:
30930022
12.

Risk of Stroke in Liver Cirrhosis: A Systematic Review and Meta-Analysis.

Zheng K, Yoshida EM, Tacke F, Li Y, Guo X, Qi X.

J Clin Gastroenterol. 2020 Jan;54(1):96-105. doi: 10.1097/MCG.0000000000001201.

PMID:
30882537
13.

Early Persistent Progressive Acute Kidney Injury and Graft Failure Post Liver Transplantation.

Hussaini T, Yoshida EM, Partovi N, Erb SR, Scudamore C, Chung S, Marquez V.

Transplant Direct. 2019 Feb 20;5(3):e429. doi: 10.1097/TXD.0000000000000868. eCollection 2019 Mar.

14.

Epidemiology and liver transplantation burden of primary biliary cholangitis: a retrospective cohort study.

Yoshida EM, Mason A, Peltekian KM, Shah H, Thiele S, Borrelli R, Fischer A.

CMAJ Open. 2018 Dec 21;6(4):E664-E670. doi: 10.9778/cmajo.20180029. Print 2018 Oct-Dec.

15.

Early liver transplant for severe alcoholic hepatitis: establishing a new frontier by ignoring the rule?

Zhu J, Hussaini T, Yoshida EM.

Ann Transl Med. 2018 Oct;6(20):411. doi: 10.21037/atm.2018.09.57. No abstract available.

16.

Assessing Maternity Care Providers' Knowledge of the Management of Hepatitis B in Pregnancy.

Van Ommen C, Marquez V, Lowe C, Money D, Yoshida EM, van Schalkwyk J.

J Obstet Gynaecol Can. 2019 May;41(5):616-622. doi: 10.1016/j.jogc.2018.06.011. Epub 2018 Nov 22.

PMID:
30471876
17.

Association of proton pump inhibitors with the risk of hepatic encephalopathy during hospitalization for liver cirrhosis.

Zhu J, Qi X, Yu H, Yoshida EM, Mendez-Sanchez N, Zhang X, Wang R, Deng H, Li J, Han D, Guo X.

United European Gastroenterol J. 2018 Oct;6(8):1179-1187. doi: 10.1177/2050640618773564. Epub 2018 Apr 23.

18.

In-hospital post-transplant acute hepatitis A viral (HAV) infection in a liver transplant recipient who was HAV seropositive pre-transplant.

Zhu J, Alalkim F, Hussaini T, Erb SR, Marquez V, Krajden M, Webber D, Yoshida EM.

Saudi J Gastroenterol. 2019 Jan-Feb;25(1):67-70. doi: 10.4103/sjg.SJG_230_18.

19.

Transient Elastography for Monitoring for Hepatotoxicity in Rheumatoid Arthritis Patients on Long-term Methotrexate.

Wade SD, Yoshida EM, Carruthers MN, Weinblatt ME.

J Clin Rheumatol. 2018 Aug 13. doi: 10.1097/RHU.0000000000000885. [Epub ahead of print] No abstract available.

PMID:
30106792
20.

Transplanting Hepatitis C-Seropositive, Nucleic Acid Test-Negative Donor Organs Into Hepatitis C-Negative Recipients.

Hussaini T, Krajden M, Mitchell RA, Yoshida EM.

Hepatology. 2018 Sep;68(3):1208-1209. doi: 10.1002/hep.30121. No abstract available.

PMID:
30070362
21.

Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis.

Kowalec K, Wright GEB, Drögemöller BI, Aminkeng F, Bhavsar AP, Kingwell E, Yoshida EM, Traboulsee A, Marrie RA, Kremenchutzky M, Campbell TL, Duquette P, Chalasani N, Wadelius M, Hallberg P, Xia Z, De Jager PL, Denny JC, Davis MF, Ross CJD, Tremlett H, Carleton BC.

Nat Genet. 2018 Aug;50(8):1081-1085. doi: 10.1038/s41588-018-0168-y. Epub 2018 Jul 16.

22.

Transient portal vein thrombosis in liver cirrhosis.

Qi X, Guo X, Yoshida EM, Méndez-Sánchez N, De Stefano V, Tacke F, Mancuso A, Sugawara Y, Yang SS, Teschke R, Arora A, Valla DC.

BMC Med. 2018 Jun 5;16(1):83. doi: 10.1186/s12916-018-1069-8. Review.

23.

Sofosbuvir-Based Therapy in the Pre-Liver Transplant Setting: The Canadian National Experience.

Al-Judaibi B, Thomas B, Wong P, Benmassaoud A, Chen JH, Dokus MK, Hussaini T, Bilodeau M, Burak KW, Marotta P, Yoshida EM.

Ann Hepatol. 2018 May-June;17(3):437-443. doi: 10.5604/01.3001.0011.7388. Epub 2018 Apr 9.

24.

Transplantation of a Liver Allograft From a Hepatitis C Virus Seropositive Donor With Previous Sustained Virologic Response to an Uninfected Recipient Suffering Steroid Refractory Acute Graft Rejection With No Evidence of HCV Transmission.

Mitchell RA, Hussaini T, Yau AH, Krajden M, Wright AJ, Scudamore CH, Marquez Azalgara V, Erb SR, Yoshida EM.

Transplant Direct. 2018 Feb 2;4(3):e347. doi: 10.1097/TXD.0000000000000763. eCollection 2018 Mar.

25.

Editorial: hepatocellular carcinoma as a consequence of hepatitis C direct-acting anti-virals-the great urban myth of hepatology.

Hussaini T, Zhu J, Yoshida EM.

Aliment Pharmacol Ther. 2018 May;47(10):1418-1419. doi: 10.1111/apt.14634. No abstract available.

26.

Impact of Sofosbuvir-Based Regimens for the Treatment of Hepatitis C After Liver Transplant on Renal Function: Results of a Canadian National Retrospective Study.

Faisal N, Bilodeau M, Aljudaibi B, Hirch G, Yoshida EM, Hussaini T, Ghali MP, Congly SE, Ma MM, Lilly LB.

Exp Clin Transplant. 2019 Feb;17(1):59-63. doi: 10.6002/ect.2017.0201. Epub 2018 Apr 4.

27.

Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis.

Efe C, Taii HA, Ytting H, Aehling N, Bhanji RA, Hagström H, Purnak T, Muratori L, Werner M, Muratori P, Klintman D, Schiano TD, Montano-Loza AJ, Berg T, Larsen FS, Alkhouri N, Ozaslan E, Heneghan MA, Yoshida EM, Wahlin S.

Dig Dis Sci. 2018 May;63(5):1348-1354. doi: 10.1007/s10620-018-5011-x. Epub 2018 Mar 22.

PMID:
29569003
28.

Let's Talk About B: Barriers to Hepatitis B Screening and Vaccination Among Asian and South Asian Immigrants in British Columbia.

Zibrik L, Huang A, Wong V, Novak Lauscher H, Choo Q, Yoshida EM, Ho K.

J Racial Ethn Health Disparities. 2018 Dec;5(6):1337-1345. doi: 10.1007/s40615-018-0483-0. Epub 2018 Mar 19.

PMID:
29557047
29.

Insights into the hepatocellular carcinoma patient journey: results of the first global quality of life survey.

Gill J, Baiceanu A, Clark PJ, Langford A, Latiff J, Yang PM, Yoshida EM, Kanavos P.

Future Oncol. 2018 Jul;14(17):1701-1710. doi: 10.2217/fon-2017-0715. Epub 2018 Mar 15.

30.

Transplantation as disease modifying therapy in adults with inherited metabolic disorders.

Sirrs S, Hannah-Shmouni F, Nantel S, Neuberger J, Yoshida EM.

J Inherit Metab Dis. 2018 Sep;41(5):885-896. doi: 10.1007/s10545-018-0141-z. Epub 2018 Feb 1. Review.

PMID:
29392586
31.

Clinical characteristics and outcomes of traditional Chinese medicine-induced liver injury: a systematic review.

Wang R, Qi X, Yoshida EM, Méndez-Sánchez N, Teschke R, Sun M, Liu X, Su C, Deng J, Deng H, Hou F, Guo X.

Expert Rev Gastroenterol Hepatol. 2018 Apr;12(4):425-434. doi: 10.1080/17474124.2018.1427581. Epub 2018 Jan 18. Review.

PMID:
29323538
32.

Annals of Hepatology: Viewpoints from Afar.

Yoshida EM, Qi X.

Ann Hepatol. 2018 January-February;17(1):4-7. doi: 10.5604/01.3001.0010.7528. No abstract available.

33.

Primary Biliary Cholangitis in British Columbia First Nations: Clinical features and discovery of novel genetic susceptibility loci.

Asuri S, McIntosh S, Taylor V, Rokeby A, Kelly J, Shumansky K, Field LL, Yoshida EM, Arbour L.

Liver Int. 2018 May;38(5):940-948. doi: 10.1111/liv.13686. Epub 2018 Jan 23.

PMID:
29297981
34.

Ischemic stroke in liver cirrhosis: epidemiology, risk factors, and in-hospital outcomes.

Zhang X, Qi X, Yoshida EM, Méndez-Sánchez N, Hou F, Deng H, Wang X, Qiu J, He C, Wang S, Guo X.

Eur J Gastroenterol Hepatol. 2018 Feb;30(2):233-240. doi: 10.1097/MEG.0000000000001011.

PMID:
29189394
35.

Supersonic shear imaging for the diagnosis of liver fibrosis and portal hypertension in liver diseases: a meta-analysis.

Deng H, Qi X, Zhang T, Qi X, Yoshida EM, Guo X.

Expert Rev Gastroenterol Hepatol. 2018 Jan;12(1):91-98. doi: 10.1080/17474124.2018.1412257. Epub 2017 Dec 8. Review.

PMID:
29186994
36.

The Cedar Project: mortality among young Indigenous people who use drugs in British Columbia.

Jongbloed K, Pearce ME, Pooyak S, Zamar D, Thomas V, Demerais L, Christian WM, Henderson E, Sharma R, Blair AH, Yoshida EM, Schechter MT, Spittal PM; Cedar Project Partnership.

CMAJ. 2017 Nov 6;189(44):E1352-E1359. doi: 10.1503/cmaj.160778.

37.

Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.

Janssen HLA, Brunetto MR, Kim YJ, Ferrari C, Massetto B, Nguyen AH, Joshi A, Woo J, Lau AH, Gaggar A, Subramanian GM, Yoshida EM, Ahn SH, Tsai NCS, Fung S, Gane EJ.

J Hepatol. 2018 Mar;68(3):431-440. doi: 10.1016/j.jhep.2017.10.027. Epub 2017 Dec 11.

PMID:
29104121
38.

Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.

Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Bräu N, Brown A, Pol S, Leroy V, Persico M, Moreno C, Colombo M, Yoshida EM, Nelson DR, Collins C, Lei Y, Kosloski M, Mensa FJ.

N Engl J Med. 2017 Oct 12;377(15):1448-1455. doi: 10.1056/NEJMoa1704053.

39.

Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting.

Thein HH, Qiao Y, Zaheen A, Jembere N, Sapisochin G, Chan KKW, Yoshida EM, Earle CC.

PLoS One. 2017 Oct 10;12(10):e0185198. doi: 10.1371/journal.pone.0185198. eCollection 2017.

40.

Immunosuppression Practices in Liver Transplantation: A Survey of North American Centers.

Hussaini T, Turgeon RD, Partovi N, Erb SR, Scudamore CH, Yoshida EM.

Exp Clin Transplant. 2018 Oct;16(5):550-553. doi: 10.6002/ect.2017.0096. Epub 2017 Aug 28.

41.

Transplanting Kidney Allografts from Hepatitis C Infected Donors into Hepatitis C Uninfected Recipients: Re-Thinking the Thinker Trial.

Hussaini T, Yoshida EM.

Ann Hepatol. 2017 Sep-Oct;16(5):702-703. doi: 10.5604/01.3001.0010.2708.

42.

Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.

Lawitz E, Buti M, Vierling JM, Almasio PL, Bruno S, Ruane PJ, Hassanein TI, Muellhaupt B, Pearlman B, Jancoriene L, Gao W, Huang HC, Shepherd A, Tannenbaum B, Fernsler D, Li JJ, Grandhi A, Liu H, Su FH, Wan S, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Yoshida EM.

Lancet Gastroenterol Hepatol. 2017 Nov;2(11):814-823. doi: 10.1016/S2468-1253(17)30163-2. Epub 2017 Aug 10.

PMID:
28802814
43.

Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting.

Thein HH, Isaranuwatchai W, Qiao Y, Wong K, Sapisochin G, Chan KKW, Yoshida EM, Earle CC.

Cancer Med. 2017 Sep;6(9):2017-2033. doi: 10.1002/cam4.1119. Epub 2017 Aug 8.

44.

Editorial: hepatitis C direct acting anti-viral agents and the kidney.

Hussaini T, Yoshida EM.

Aliment Pharmacol Ther. 2017 Aug;46(3):378-379. doi: 10.1111/apt.14161. No abstract available.

45.

Rivaroxaban recanalized occlusive superior mesenteric vein thrombosis, but increased the risk of bleeding in a cirrhotic patient.

Qi X, Yoshida EM, Mendez-Sanchez N, Guo X.

Liver Int. 2017 Oct;37(10):1574-1575. doi: 10.1111/liv.13511. Epub 2017 Jul 21. No abstract available.

PMID:
28675619
46.

Identifying those infected with hepatitis C virus.

Yoshida EM, Renner E, Wong P, Krajden M.

CMAJ. 2017 Jun 26;189(25):E869. doi: 10.1503/cmaj.733099. No abstract available.

47.

Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis.

Efe C, Hagström H, Ytting H, Bhanji RA, Müller NF, Wang Q, Purnak T, Muratori L, Werner M, Marschall HU, Muratori P, Gunşar F, Klintman D, Parés A, Heurgué-Berlot A, Schiano TD, Cengiz M, May-Sien Tana M, Ma X, Montano-Loza AJ, Berg T, Verma S, Larsen FS, Ozaslan E, Heneghan MA, Yoshida EM, Wahlin S.

Clin Gastroenterol Hepatol. 2017 Dec;15(12):1950-1956.e1. doi: 10.1016/j.cgh.2017.06.001. Epub 2017 Jun 8.

PMID:
28603052
48.

Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.

Feld JJ, Ramji A, Shafran SD, Willems B, Marotta P, Huchet E, Vachon ML, Svarovskaia ES, Huang KC, Hyland RH, Yun C, Massetto B, Brainard DM, McHutchison JG, Tam E, Bailey R, Cooper C, Yoshida EM, Greenbloom S, Elkhashab M, Borgia S, Swain MG.

Clin Infect Dis. 2017 Jul 1;65(1):13-19. doi: 10.1093/cid/cix289.

PMID:
28535298
49.

Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant.

Yoshida EM, Kwo P, Agarwal K, Duvoux C, Durand F, Peck-Radosavljevic M, Lilly L, Willems B, Vargas H, Kumar P, Brown RS Jr, Horsmans Y, De-Oertel S, Arterburn S, Dvory-Sobol H, Brainard DM, McHutchison JG, Terrault N, Rizzetto M, Müllhaupt B.

Ann Hepatol. 2017 May - Jun;16(3):375-381. doi: 10.5604/16652681.1235480.

50.

The Direct-Acting Antivirals for Hepatitis C Virus and the Risk for Hepatocellular Carcinoma.

Chinchilla-López P, Qi X, Yoshida EM, Méndez-Sánchez N.

Ann Hepatol. 2017 May - Jun;16(3):328-330. doi: 10.5604/16652681.1235473.

Supplemental Content

Loading ...
Support Center